Skip to content

NICE

Uncle Sam hitting a high striker with a large hammer. The high striker show a lambda at the top.

Cost-effectiveness thresholds under political pressure: where are the health economists?

The UK government is reportedly preparing to raise NICE’s cost-effectiveness threshold by 25%, as a bargaining chip to avoid US pharmaceutical tariffs. It’s time for health economists to reclaim this space and defend evidence-based decision-making.

Blue wheelchair sign with arrow below it

The ‘wheelchair example’ – why it should be dropped from EQ-5D valuation tasks

The EQ Valuation Technology (EQ-VT) protocol has been widely used in the valuation of EuroQol instruments, including in over 25 national EQ-5D-5L value sets and, in an adapted form, the valuation of EQ-5D-Y-3L. Adapted versions of it are also currently… Read More »The ‘wheelchair example’ – why it should be dropped from EQ-5D valuation tasks